The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Should we treat TP53-mutated high-risk myeloid neoplasms in older patients?
 
Talha Badar
Honoraria - MorphoSys; Takeda
Research Funding - Takeda
 
Mobachir El Kettani
No Relationships to Disclose
 
Kashish Shah
No Relationships to Disclose
 
Omer Jamy
Consulting or Advisory Role - Ascentage Pharma; MaaT Pharma; Terns Pharmaceuticals
 
Rory Shallis
Consulting or Advisory Role - Kura Oncology; Rigel; SERVIER; Syndax
 
Kendall Diebold
No Relationships to Disclose
 
Alexander Coltoff
No Relationships to Disclose
 
Aaron Goldberg
No Relationships to Disclose
 
Anand Patel
Consulting or Advisory Role - Abbvie; Jazz Pharmaceuticals
Research Funding - Incyte; Kronos Bio (Inst); Pfizer (Inst); SERVIER; Sumitomo Dainippon Pharma Oncology
 
Jan Philipp Bewersdorf
No Relationships to Disclose
 
Charles Foucar
No Relationships to Disclose
 
Yasmin Abaza
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Celgene; Geron; Kite/Gilead; Pfizer; Rigel; SERVIER
Research Funding - Abbvie (Inst); ALX Oncology (Inst); Biomea Fusion (Inst); Biosight (Inst); Curis (Inst); Novartis (Inst)
 
Neil Palmisiano
No Relationships to Disclose
 
Adam DuVall
No Relationships to Disclose
 
Vamsi Kota
Consulting or Advisory Role - Novartis; Pfizer; SERVIER
 
Amer Zeidan
Honoraria - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Consulting or Advisory Role - Abbvie; Agios; Akeso Biopharma; ALX Oncology; Amgen; Astellas Pharma; Astex Pharmaceuticals; BeiGene; BioCryst; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chiesi; Daiichi Sankyo; Epizyme; Faron Pharmaceuticals; Genentech; Geron; Gilead Sciences; Glycomimetics; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Keros Therapeutics; Kura Oncology; Kyowa Kirin International; lava therapeutics; Mendus; Notable Labs; Novartis; Orum Therapeutics; Otsuka; Pfizer; Regeneron; Rigel; Schrodinger; SERVIER; Shattuck Labs; Sumitomo Pharma Oncology; Syndax; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda; Treadwell Therapeutics; Vincerx Pharma; Zentalis
Research Funding - Abbvie (Inst); Amgen; Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Geron; Kura Oncology; Novartis (Inst); Otsuka; Shattuck Labs; Syros Pharmaceuticals; Takeda (Inst)
 
Ehab Atallah
No Relationships to Disclose
 
Mark Litzow
No Relationships to Disclose